@entity2002 and risk of XXXX . The Framingham Study.

@entity1 @entity2002 @entity64 @entity6 @entity301 @entity65
During the tenth biennial examination of the Framingham Study, 1315 @entity1 who were free of @entity65 had @entity2002 levels measured. During the ensuing 12 years, @entity65 developed in 165 @entity1 and 147 @entity1 . For both sexes, the risk of @entity65 was correlated positively to antecedent @entity2002 values higher than the 1.3 to 7.0 g/L (126 to 696 mg/dL) range. The magnitude of the risk diminished with advancing age in @entity1 but not in @entity1 . Risk for @entity301 also was significantly related to @entity2002 level. Here, the magnitude of risk displayed diminishing impact with age, again only in @entity1 . Risk of @entity64 increased progressively with @entity2002 level in @entity1 but not in @entity1 . The impact of @entity2002 value, considered as a separate variable, on @entity65 was comparable with the major risk factors, such as blood pressure, hematocrit, adiposity, cigarette smoking, and @entity6 . @entity2002 values were also significantly related to these risk factors. Taking all these into account in a multivariate analysis, @entity2002 level was still significantly related to the incidence of @entity65 in @entity1 and marginally significant in @entity1 . For @entity301 , the @entity2002 level was significant for both @entity1 and @entity1 . Elevated @entity2002 level is a predictor of @entity65 that should be added to the @entity65 factor profile.
